Liver Disease as a Predictor of New-Onset Atrial Fibrillation

William A. Huang, MD; Eric A. Dunipace, MS; Julie M. Sorg, MSN; Marmar Vaseghi, MD, PhD

Background—Impact of liver disease on development of atrial fibrillation (AF) is unclear. The purpose of the study was to evaluate prevalence of AF in the setting of liver disease and whether increasing severity of liver disease, using Model for End-Stage Liver Disease (MELD), is independently associated with increased risk of AF.

Methods and Results—Retrospective data analysis of 1727 patients with liver disease evaluated for liver transplantation between 2006 and 2015 was performed, and patient characteristics were analyzed from billing codes and review of medical records. Multivariable time-dependent Cox proportional hazards model was performed to determine effect of increasing MELD score on risk of developing AF. Prevalence of AF was 11.2%. Incidence of AF at median follow-up time of 1.04 years was 8.5%. Both prevalence and incidence of AF increased with increasing MELD scores. Prevalence of AF was 3.7%, 6.4%, 16.7%, and 20.2% corresponding with MELD quartiles 1 to 10, 11 to 20, 21 to 30, and >30, respectively. Compared with patients with MELD quartile 1 to 10, patients with MELD quartile of 11 to 20 had hazard ratio of 2.73 (confidence interval, 1.47–5.07), those in the MELD quartile of 21 to 30 had a hazard ratio of 5.17 (confidence interval, 2.65–10.09), and those with MELD values >30 had hazard ratio of 9.33 (confidence interval, 3.93–22.14) for development of new-onset AF. Other significant variables associated with new-onset AF were age, sleep apnea, valvular heart disease, hemodynamic instability, and reduced left ventricular ejection fraction <50% (hazard ratio, of 1.06, 2.17, 3.21, 2.00, and 2.44, respectively).

Conclusions—Prevalence and incidence of AF in patients with liver disease is high. Severity of liver disease, as measured by MELD, is an important predictor of new-onset AF. This novel finding suggests an interaction between inflammatory and neurohormonal changes in liver disease and pathogenesis of AF. (J Am Heart Assoc. 2018;7:e008703. DOI: 10.1161/JAHA.118.008703.)

Key Words: atrial fibrillation • atrial fibrillation arrhythmia • cirrhosis • liver disease • Model for End-Stage Liver Disease

Liver disease can affect circulating inflammatory peptides and lead to autonomic dysfunction, creating a proarrhythmic substrate.1–4 An elevated risk of atrial fibrillation (AF) among patients with liver disease and structurally normal hearts seems plausible given that inflammation and autonomic dysfunction have been shown to contribute to pathogenesis of AF.5 However, studies on incidence and prevalence of AF in patients with liver disease are few and have shown mixed results.6,7 In addition, results of these studies have been confounded by the lack of assessment of liver disease severity in the specific population studied. In this study, we hypothesized that the risk of new-onset AF is driven by severity of liver disease. We therefore hypothesized that increasing Model for End-Stage Liver Disease (MELD) values is associated with new-onset AF, after adjusting for other comorbidities and risk factors.

Methods

As per the Journal of American Heart Association (JAHA) implementation of transparency and openness policy, the data, analytical methods, and study materials will be made available to other researchers for purposes of reproducing the results or replicating the procedure upon request.

Study Population

Retrospective data analysis of consecutive patients who were diagnosed with liver disease between January 2006 and December 2015 and were evaluated for potential liver transplantation (LT) was performed. The electronic health records database was made available by the University of California, Los
Liver Disease and Atrial Fibrillation

Huang et al

Clinical Perspective

What Is New?

- Prevalence of atrial fibrillation (AF) in patients with liver disease is high.
- This large, retrospective study shows a clear association between liver disease and development of AF, independent of other risk factors for AF.
- Severity of liver disease, as measured by Model for End-Stage Liver Disease, is an important predictor of new-onset AF, with increasing risk of developing this arrhythmia with increased Model for End-Stage Liver Disease values.

What Are the Clinical Implications?

- Severity of liver disease, as measured by Model for End-Stage Liver Disease, is an important independent predictor of new-onset AF.
- This novel finding suggests an interaction between inflammatory and neurohormonal changes in liver disease and pathogenesis of AF.
- Given the prevalence of AF in this population, cardiologists and hepatologists should consider screening for symptoms and signs of AF in patients with liver disease, particularly in those with higher Model for End-Stage Liver Disease values.

MELD Score

Severity of liver disease was assessed by MELD score and calculated using the formula:

\[
\text{MELD Score} = 9.57 \times \log_{10}(\text{creatinine mg/dL}) + 3.78 \\
+ \log_{10}(\text{bilirubin mg/dL}) + 11.20 \\
+ \log_{10}(\text{INR}) + 6.43.
\]

MELD values for each patient were calculated and used for survival analysis. MELD scores confounded by use of warfarin and argatroban were treated as unknown values and excluded from analysis.

Baseline Characteristics and Assessment of AF

Baseline characteristics were collected from patient medical records, including physician notes, laboratory results, medications, billing codes, ECGs, ambulatory monitors, and echocardiograms. AF diagnosis was obtained from physician notes and billing codes and verified by detailed review of medical records, which included review of all available ECGs and ambulatory monitors. AF prevalence was calculated using the last available time point preceding LT and after the first presentation for clinical evaluation for liver disease or LT. Severe valvular heart disease was assessed from echocardiographic reports and defined as presence of any severe valvular regurgitation or stenosis. Echocardiographic reports were also used to evaluate for moderate or severe left atrial (LA) enlargement. To assess whether severity of liver disease was associated with new-onset AF, occurrence of new-onset AF after first available MELD score was assessed. Patients were followed up until occurrence of LT, death, or loss to follow-up. Patients were then binned into quartiles of MELD categories, which included those with MELD score of 1 to 10 as the lowest quartile, followed by 10 to 20, 20 to 30, and >30. Percentages of patients with missing variables are shown in Table S1.

Statistical Analysis

Continuous variables were assessed as means with SDs or medians with 25% to 75% percentiles, and categorical variables as percentages. Patient characteristics by occurrence of AF were assessed using a 2-tailed Student t test. Univariable analyses of patient characteristics were performed during the time frame of MELD score availability. Clinically relevant variables, such as age and sex, as well as statistically significant variables (P<0.05) on univariable analysis, were included in the multivariable analysis. Multivariable time-dependent Cox regression analysis was performed to analyze the effect of MELD score on incidence of new-onset AF, adjusted for age, sex, reduced left ventricular (LV) ejection fraction (LVEF) <50%, LA enlargement, LV hypertrophy, severe valvular heart disease, portal hypertension, hypertension, diabetes mellitus, hemodynamic instability, and sleep apnea. Missing data were imputed using an Expectation-Maximization algorithm developed by Honaker et al for missing data in time series and 15 multiply imputed data sets generated. All estimates were combined using Rubin’s rules and P values combined using methods from Meng and Rubin and Marshall et al. In addition, the multivariable time-dependent Cox regression analysis was also performed on available (nonimputed data) to further confirm the results. For survival analysis, only patients with at least 2 MELD scores from distinct dates were considered for analysis. All analyses were performed using the R statistical package (Version 3.4.2; R Foundation for Statistical Computing, Vienna, Austria). P≤0.05 was considered statistically significant. The data, analytical methods, and study materials will be/have been made available to other researchers for purposes of reproducing the results or replicating the procedure.

DOI: 10.1161/JAHA.118.008703

Journal of the American Heart Association

2
Results

Patient Characteristics

Between 2006 and 2015, 1727 patients (mean age, 54.4±12.2; 40% female) were diagnosed with liver disease and evaluated for possible LT. Median follow-up time was 1.04 years (interquartile range, 2 months to 3 years).

Baseline characteristics are shown in Table. Mean MELD score in the overall population was 17.5±8.5, and 28% of patients underwent LT at the end of follow-up. Mean LVEF was 61±8%, sleep apnea was present in 0.5%, severe valvular heart disease in 0.3%, and moderate or severe LA enlargement was 0.3%. LV hypertrophy was present 0.5%, and LV diastolic dysfunction was present in 6.4% of the population. Beta-blocker use at baseline in the population was 5.7%, and during the follow-up period, was 11.9 new prescriptions per 100 patient years. Baseline CHA2DS2-VASc was 0.83 at baseline and baseline HAS-BLED score was 2.0.

Including pre-existing AF at the time of evaluation, overall prevalence of AF among this population was 11.2% (confidence interval [CI], 9.8–12.7). AF prevalence by final MELD score (Figure 1) was 3.7% in the lowest MELD quartile and 20.2% in highest quartile. Freedom from AF (Figure 2) decreased over time with 8.5% of patients experiencing new-onset AF over the median follow-up period. Incidence of new-onset AF by MELD categories (1–10, 11–20, and 21–30) over a 12-month period is shown in Figure 3. There was a trend of increasing incidence of AF as MELD severity increased (P=0.056). Of note, patients in the highest MELD group (>30) had a very short median follow-up time (<1 month) attributed to either death or LT.
On univariable analysis (Table S2), variables commonly associated with AF, including age, severe valvular heart disease, hemodynamic instability, LVEF, LA enlargement, and sleep apnea, were significantly associated with new-onset AF. Therefore, these variables, in addition to categories of MELD score, were included in the final multivariable analysis, which included: age, diabetes mellitus, hemodynamic instability, hypertension, LA enlargement, LV hypertrophy, MELD score groups (1–10, 11–20, 21–30, and >30), portal hypertension, LVEF, sleep apnea, and valvular heart disease. Patient characteristics by occurrence of new-onset AF are shown in Table S3.

Using multivariable time-dependent Cox proportional hazard regression analysis (Figure 4), increasing severity of MELD was independently associated with new-onset AF. Specifically, as compared with patients in the lowest quartile (MELD 1–10), those in the MELD group of 11 to 20 had a hazard ratio (HR) of 2.73 (CI, 1.47–5.07), those with MELD score of 21 to 30 had an HR of 5.41 (CI, 2.77–10.55), and those in the highest quartile (MELD >30) had an HR of 9.33 (CI, 3.93–22.14) for new-onset AF. Other variables that were significantly associated with new-onset AF were age (HR=1.06 [CI, 1.04–1.08]), sleep apnea (HR=2.2 [CI, 1.02–4.61]), severe valvular heart disease (HR=3.21 [CI, 1.68–6.11]), hemodynamic instability (HR=2.00 [CI, 1.24–3.25]), and reduced LVEF (HR=2.44 [CI, 1.44–4.14]). Based on the Cox proportional hazard model, a predicted freedom from AF curve was constructed for the quartiles of MELD scores and is also shown in Figure 4. Similar results were obtained with the Cox proportional hazard model using available (nonimputed) data (Table S4).

With regard to stroke, rate of stroke was 1.6 events per 100 years of follow-up in patients with AF (ischemic stroke rate of 1.3% and hemorrhagic stroke rate of 0.6%). CHA2DS2-VASc score in these patients was 1.1/C6 1.0, likely explaining the low incidence of stroke in this patient population with otherwise low comorbidities. Risk of stroke (both ischemic and hemorrhagic) did significantly increase with increasing MELD score (P<0.001; Tables S5 and S6).

Discussion

Major Findings

In this large, retrospective study, incidence and prevalence of AF in liver disease was high and severity of liver disease, as measured by MELD, was found to be a novel risk factor for new-onset AF, after adjusting for other traditional risk factors.

End-Stage Liver Disease and AF

Although many variables play a role in the pathogenesis of AF, liver disease has not been traditionally viewed as 1 of these risk factors. The few studies that have evaluated prevalence and risk of developing AF in patients with liver disease have shown mixed results. Mwalitsa et al evaluated 335 patients with cirrhosis and found that, over 24 months of follow-up, there was no association between cirrhosis or MELD score and new-onset AF. It is possible that the small sample size of this study and the method used for verifying AF could have
underestimated the incidence of AF in this population. In another study of 1302 cirrhotic patients, incidence of AF was found to be very low at 0.15%, and this study suggested that liver disease may be protective against AF. However, in this study, disease severity was not assessed and intermittent ECGs were used for verification of AF diagnosis, leading to underdiagnosis of asymptomatic episodes. On the other hand, Lee et al. focused on new-onset AF and found a 46% relatively higher risk of AF in cirrhotic patients compared with noncirrhotic patients. Given the small number and controversial results of these previous studies, we hypothesized that severity of liver disease, as assessed by MELD score, would be independently associated with increased risk of AF after adjusting for other traditional cardiac and noncardiac risk factors, such as sleep apnea. We noted an AF prevalence of 20.2% in patients with the highest MELD category with a new AF incidence of 8.5% at 12 months of follow-up in the overall population. Mean age of our population was only 54.4 ± 12 years. Based on a study by Wilke et al looking at 8.3 million people in Germany, prevalence of AF has been reported to be between 1% and 2% in men (ages 50–55 and 55–59 years, respectively) and 0.4% to 0.8% in women (ages 50–55 and 55–59 years, respectively). Prevalence and incidence of AF were much higher in our patient population with liver disease, despite the fact that many of the previously reported historical controls had presence of cardiac risk factors for AF, such as hypertension and heart failure. High prevalence of AF, particularly as liver disease progresses, suggests that both cardiologists and

Clinical Implications

Patients with liver disease have been traditionally viewed as having low cardiac comorbidities, with a focus placed on treatment of associated renal dysfunction and coagulopathy. A previous study had even suggested that liver disease may play a protective role against the development of AF. Our study suggests that patients with cirrhosis are at increased risk of AF, with increasing risk of developing AF as their MELD score rises. Severity of liver disease was independently associated with increased risk of AF after adjusting for other traditional cardiac and noncardiac risk factors, such as sleep apnea. We noted an AF prevalence of 20.2% in patients with the highest MELD category with a new AF incidence of 8.5% at 12 months of follow-up in the overall population. Mean age of our population was only 54.4 ± 12 years. Based on a study by Wilke et al looking at 8.3 million people in Germany, prevalence of AF has been reported to be between 1% and 2% in men (ages 50–55 and 55–59 years, respectively) and 0.4% to 0.8% in women (ages 50–55 and 55–59 years, respectively). Prevalence and incidence of AF were much higher in our patient population with liver disease, despite the fact that many of the previously reported historical controls had presence of cardiac risk factors for AF, such as hypertension and heart failure. High prevalence of AF, particularly as liver disease progresses, suggests that both cardiologists and
hepatologists should be aware of the emerging risk of AF, inquire about arrhythmia symptoms, and consider periodic evaluations with ECGs and ambulatory monitors.

Higher prevalence of AF as well as increasing incidence of AF with increasing severity of liver disease bring to the forefront the question of benefit versus risk of anticoagulation. The benefit of anticoagulation for ischemic stroke prevention in patients with liver disease and AF remains unknown. Few studies have evaluated the benefit of anticoagulation systematically or in a randomized fashion. Kuo et al evaluated liver disease patients with CHA2DS2-VASc score ≥2 in the setting of AF and showed a reduction in ischemic stroke events in patients treated with warfarin compared with those with and without antiplatelet therapy, notably without increased intracranial hemorrhage. However, an increased risk of hemorrhagic stroke and intracranial hemorrhage has been reported in patients with cirrhosis as compared with those without, and in 1 study was reported to be higher than ischemic stroke risk.

A tailored strategy has been proposed and includes anticoagulation in the setting of less-severe liver disease, while refraining from anticoagulation in more severe cirrhotic patients with AF. The results of our study, demonstrating a high prevalence of AF and increasing incidence of AF in the setting of more-advanced liver disease, highlight the need for better designed studies in this specific population to define the benefit and risk of anticoagulation, particularly with the advent of novel oral anticoagulants. It is possible that patients at high risk of bleeding and stroke may also benefit from LA appendage closure devices, a question that could not be assessed in our study, given the low overall CHA2DS2-VASc score and low incidence of comorbidities in this population.

It has been suggested that AF is associated with worsened outcomes in the perioperative period and immediate postoperative period in patients undergoing LT. Given the findings of this study, AF is likely a marker of illness severity rather than a major cause of poor outcomes.

Potential Mechanisms Behind Development of AF in Cirrhosis

Liver disease can directly or indirectly influence the pathogenesis of AF. The autonomic nervous system is known to play a significant role in development of AF. Abnormal autonomic neurotransmission, with increased parasympathetic and sympathetic activation, is associated with AF. Vagal afferent and efferent fibers also innervate the portal vein, hepatic arteries, and biliary ducts in addition to liver parenchyma. Specifically, autonomic dysfunction has been observed in the setting of portal hypertension and nonalcoholic fatty liver disease, and denervation of liver parenchyma has been observed in cirrhosis. Cardiac metaiodobenzylguanidine studies have shown an increased washout rate consistent with abnormal myocardial norepinephrine reuptake in patients with cirrhosis. In addition, patients with cirrhosis have been shown to have significantly decreased heart rate variability and baroreflex sensitivity with increased prevalence of abnormal heart rate variability with increasing severity of liver disease. Finally, improvements in autonomic indices are observed post-LT.

Cirrhosis can also lead to increased levels of neuropeptides that have been shown to play a role in development of AF. Vasoactive intestinal peptide is increased in the setting of cirrhosis, possibly attributed to decreased turnover by the liver. Vasoactive intestinal peptide has also been implicated in the onset of vagally mediated AF. Whereas low and moderate levels of vagal nerves stimulation have been shown to be protective in preventing AF, vasoactive intestinal peptide is coreleased with acetylcholine during high-level vagal nerve stimulation, shortening action potential duration, increasing atrial action potential duration spatial heterogeneity, and causing intra-atrial conduction block.

Another potential mechanism behind the elevated risk of AF in the setting of cirrhosis is the elevated levels of galectin-3 observed in patients with liver disease. Galectin-3 is implicated in fibrosis of both the liver and heart, and associated with increased incidence of AF. Other potential mediators that share the common pathway of fibrosis and could play a role include transforming growth factor beta and connective tissue growth factor. Also, many inflammatory cytokines, such as interleukin-6, interleukin-8, and tumor necrosis factor-alpha, and oxidative radicals, such as superoxides and peroxynitrite, are elevated in the setting of significant liver disease and also play a role in development of AF.

Finally, many circulatory cytokines and neuropeptides that play a role in AF are upregulated by the autonomic dysfunction that occurs in liver disease.

Limitations

This study is a single-center retrospective study and represents outcomes at a specialized center for evaluation of patients with liver disease. To best capture AF prevalence, patients with cirrhosis undergoing evaluation for LT were selected, because this group at our center undergoes extensive and rigorous cardiac evaluation regardless of cardiac history. Focusing efforts on this population, however, may create a bias toward patients who do not have a significant burden of comorbidities that would preclude consideration for transplantation. However, using a population with less comorbidity allows for a more accurate assessment of the impact of liver disease on development of AF, the primary goal of this study. Using International Classification of Diseases, Ninth Revision (ICD-9) billing code data to identify comorbidities associated with AF, such as sleep apnea, has limitations. However, in this study, many
of the risk factors previously reported to be associated with AF continued to be statistically significant in our multivariable model. Of note, in this study, manual chart review was performed to ensure that all AF diagnoses had also been documented on physician notes, ECGs, and ambulatory monitors in addition to ICD-9 codes. Finally, although we performed a review of all available clinical data to verify the diagnosis of AF, it is possible that patients with asymptomatic AF were overlooked, and therefore, despite the higher prevalence of AF observed in this study, it may yet represent a conservative estimate as to the true prevalence of AF in this population. Finally, we noted a higher prevalence and incidence of AF in patients with liver disease as compared with previous studies that reported the prevalence and incidence of AF by age in the general population. However, we did not have access to data of similar age-/sex-matched controls without liver disease with similar CHA2DS2-VAsc scores to show a lower incidence of AF in a similar population without liver disease.

Conclusions
Prevalence of AF in patients with liver disease is notable. Incidence of AF increases with increasing severity of liver disease, which is independently associated with new-onset AF, even after adjusting for other common risk factors. This finding may provide additional mechanistic insight into the pathogenesis of AF, which shares the underlying link of autonomic dysfunction and inflammation, known to play a role in development of AF. Given the prevalence of AF in this population, cardiologists and hepatologists should consider screening for symptoms and signs of AF in patients with liver disease, particularly in patients with higher MELD values. The results also highlight the need for future well-designed studies to evaluate risks and benefits of anticoagulation in the setting of liver disease.

Sources of Funding
This work was supported by the NIH/National Center for Advancing Translational Science (NCATS) UCLA CTSI Grant Number UL1TR000124 and NIH1DP21 DP2 HL132356-01 to Vaseghi.

Disclosures
None.

References
1. Dumcke CW, Moller S. Autonomic dysfunction in cirrhosis and portal hypertension. Scand J Clin Lab Invest. 2008;68:437–447.

2. Rangari M, Sinha S, Kapoor D, Mohan JC, Sarin SK. Prevalence of autonomic dysfunction in cirrhotic and noncirrhotic portal hypertension. Am J Gastroenterol. 2002;97:707–713.

3. Voigt MD, Trey G, Levitt NS, Raine R, Lombard CJ, Robson SC, Gordon G, Kirsch RE. Autonomic neuropathy in extra-hepatic portal vein thrombosis: evidence for impaired autonomic reflex arc. J Hepatol. 1997;26:634–641.

4. Patel P, Dokainish H, Taisi P, Lakkis N. Update on the association of inflammation and atrial fibrillation. J Cardiovasc Electrophysiol. 2010;21:1064–1070.

5. Chen PS, Chen LS, Fishbein MC, Lin SF, Nattel S. Role of the autonomic nervous system in atrial fibrillation: pathophysiology and therapy. Circ Res. 2014;114:1500–1515.

6. Lee H, Choi EK, Rhee TM, Lee SR, Lim WH, Kang SH, Han KD, Cha MJ, Oh S. Cirrhosis is a risk factor for atrial fibrillation: a nationwide, population-based study. Liver Int. 2017;37:1640–1647.

7. Mualufsa JP, Maimone S, Filomina R, Aliabrandi S, Saitta C, Caccamo G, Cacciola I, Spinella R, Oliva G, Lembo T, Vadaia D, Gambino G, Raimondo G. Sudden Q. Atrial fibrillation in patients with cirrhosis. Liver Int. 2016;36:395–400.

8. AMELIA II: a program for missing data [computer program]. 2009.

9. Meng XL, Rubin DB. Performing likelihood ratio tests with multiply-imputed data sets. Biometrika. 1992;79:103–111.

10. Marshall A, Altman DG, Holder RL, Royston P. Combining estimates of interest in prognostic modelling studies after multiple imputation: current practice and guidelines. BMC Med Res Methodol. 2009;9:57.

11. Little RJA, Rubin DB. Statistical Analysis With Missing Data. New York, NY: John Wiley & Sons; 2002.

12. R Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2017.

13. Zamirian M, Sarmadi T, Aghasaeideh K, Kazemi MB. Liver cirrhosis prevents atrial fibrillation: a reality or just an illusion? J Cardiovasc Dis Res. 2012;3:109–112.

14. Xia VW, Worapot A, Huang S, Dillon A, Budzieno V, Backon A, Agopian VG, Askoys O, Vorobiof G, Busuttil RW, Steadman RH. Postoperative atrial fibrillation in liver transplantation. Am J Transplant. 2015;15:687–694.

15. Wilke T, Groth A, Mueller S, Pfannkuche M, Verheyen F, Linder R, Maywald U, Baurersachs R, Breithardt G. Incidence and prevalence of atrial fibrillation: an analysis based on 8.3 million patients. Europace. 2013;15:486–493.

16. Kuo L, Chao TF, Liu CJ, Lin YJ, Chung SL, Lo LW, Hu YF, Tuan TC, Liao JN, Chung FP, Chen Tj, Lip GYH, Chen SA. Liver cirrhosis in patients with atrial fibrillation: would oral anticoagulation have a net clinical benefit for stroke prevention? J Am Heart Assoc. 2017;6:e005307. DOI: 10.1161/JAHA.116.005307.

17. Parikh NS, Navi BB, Schneider Y, Jesudian A, Kamel H. Association between cirrhosis and stroke in a nationally representative cohort. JAMA Neurol. 2017;74:927–932.

18. Parikh NS, Navi BB, Kumar S, Kamel H. Association between liver disease and intracranial hemorrhage. J Stroke Cerebrovasc Dis. 2016;25:543–549.

19. Wu HY, Lin CS, Yeh CC, Hu CJ, Shih CC, Cheng SG, Chen TL, Liao CC. Cirrhosis patients’ stroke risks and adverse outcomes: two nationwide studies. Atherosclerosis. 2017;263:29–35.

20. Lee SJ, Uhm JS, Kim JY, Pak HN, Lee MH, Joung B. The safety and efficacy of vitamin K antagonist in patients with atrial fibrillation and liver cirrhosis. Int J Cardiol. 2015;180:185–191.

21. Bargheer J, Trejo-Gutierrez JP, Patel T, Rossor B, Aranda-Michel J, Yataco ML, Tamer GB. Preexisting atrial fibrillation and cardiac complications after liver transplantation. Liver Transpl. 2015;21:314–320.

22. Vannucci A, Rathor R, Vachharajani N, Chapman W, Kangra I. Atrial fibrillation in patients undergoing liver transplantation: a single-center experience. Transplant Proc. 2014;46:1432–1437.

23. Liu L, Nattel S. Differing sympathetic and vagal effects on atrial fibrillation in dogs: role of refractoriness heterogeneity. Am J Physiol. 1997;273:H805–H816.

24. Uyama N, Geerts A, Reynaert H. Neural connections between the hypothalamus and the liver. Anat Rec A Discov Mol Cell Evol Biol. 2004;280:808–820.

25. Liu YC, Hung CS, Wu YW, Lee YC, Lin YH, Lin C, Lo MT, Chan CC, Ma HP, Ho YL, Chen CH. Influence of non-alcoholic fatty liver disease on autonomic changes evaluated by the time domain, frequency domain, and symbolic dynamics of heart rate variability. PLoS One. 2013;8:e61903.

26. Lee JA, Ahmed O, Hines JE, Burt AD. Disappearance of hepatic parenchymal nerves in human liver cirrhosis. Gut. 1992;33:87–91.

27. Moller S, Mortensen C, Bendtsen F, Jensen LT, Gotze JP, Madsen JL. Cardiac sympathetic imaging with mIBG in cirrhosis and portal hypertension: relation to autonomic and cardiac function. Am J Physiol Gastrointest Liver Physiol. 2012;303:G1228–G1235.

DOI: 10.1161/JAHA.118.008703
Liver Disease and Atrial Fibrillation  Huang et al

28. Dillon JF, Plevris JN, Nolan J, Ewing DJ, Neilson JM, Bouchier IA, Hayes PC. Autonomic function in cirrhosis assessed by cardiovascular reflex tests and 24-hour heart rate variability. Am J Gastroenterol. 1994;89:1544–1547.

29. Di Stefano C, Milazzo V, Milan A, Veglio F, Maule S. The role of autonomic dysfunction in cirrhotic patients before and after liver transplantation. Review of the literature. Liver Int. 2016;36:1081–1089.

30. Henriksen JH, Staun-Olsen P, Borg Mogensen N, Fahrenkrug J. Circulating endogenous vasoactive intestinal polypeptide (VIP) in patients with uraemia and liver cirrhosis. Eur J Clin Invest. 1986;16:211–216.

31. Hunt S, Vaamonde CA, Rattassi T, Berian G, Said SI, Papper S. Circulating levels of vasoactive intestinal polypeptide in liver disease. Arch Intern Med. 1979;139:994–996.

32. Liu Y, Scherlag BJ, Fan Y, Varma V, Male S, Chaudhry MA, Huang C, Po SS. Inducibility of atrial fibrillation after GP ablations and “autonomic blockade”: evidence for the pathophysiological role of the nonadrenergic and noncholinergic neurotransmitters. J Cardiovasc Electrophysiol. 2013;24:188–195.

33. Xi Y, James Chao ZY, Yan W, Abbasi S, Yin X, Mathuria N, Patel M, Fan C, Sun J, Wu G, Wang S, Elayda M, Gao L, Wehrens XH, Lin SF, Cheng J. Neuronally released vasoactive intestinal polypeptide alters atrial electrophysiological properties and may promote atrial fibrillation. Heart Rhythm. 2015;12:1352–1361.

34. Xi Y, Wu G, Ai T, Cheng N, Kalinik JM, Sun J, Abbasi S, Yang D, Fan C, Yuan X, Wang S, Elayda M, Gregoric ID, Kantharia BK, Lin SF, Cheng J. Ionic mechanisms underlying the effects of vasoactive intestinal polypeptide on canine atrial myocardium. Circ Arrhythm Electrophysiol. 2013;6:976–983.

35. Gudowska M, Gruszewska E, Cywik B, Panasiuk A, Rogalska M, Flišiak R, Szmikowski M, Chrostek L. Galectin-3 concentration in liver diseases. Ann Clin Lab Sci. 2015;45:669–673.

36. Hsu DK, Dowling CA, Jeng KC, Chen JT, Yang RY, Liu FT. Galectin-3 expression is induced in cirrhotic liver and hepatocellular carcinoma. Int J Cancer. 1999;81:519–526.

37. Lippi G, Cervellin G, Sanchis-Gomar F. Galectin-3 in atrial fibrillation: simple bystander, player or both? Clin Biochem. 2015;48:818–822.

38. Ho JE, Yin X, Levy D, Vasan RS, Magnani JW, Ellinor PT, McManus DD, Lubitz SA, Larson MG, Benjamin EJ. Galectin 3 and incident atrial fibrillation in the community. Am Heart J. 2014;167:729–734.e1.

39. Xu F, Liu C, Zhou D, Zhang L. TGF-beta/SMAD pathway and its regulation in hepatic fibrosis. J Histochem Cytochem. 2016;64:157–167.

40. Gressner OA, Gressner AM. Connective tissue growth factor: a fibrogenic master switch in fibrotic liver diseases. Liver Int. 2008;28:1065–1079.

41. Martinez-Esparza M, Tristan-Manzano M, Ruiz-Alcaraz AJ, Garcia-Penarrubia P. Inflammatory status in human hepatic cirrhosis. World J Gastroenterol. 2015;21:11522–11541.

42. Vairappan B. Endothelial dysfunction in cirrhosis: role of inflammation and oxidative stress. World J Hepatol. 2015;7:443–459.

43. Jalife J. Mechanisms of persistent atrial fibrillation. Curr Opin Cardiol. 2014;29:20–27.

44. Sovari AA. Cellular and molecular mechanisms of arrhythmia by oxidative stress. Cardiol Res Pract. 2016;2016:9656078.

45. Harada M, Van Wagoner DR, Nattel S. Role of inflammation in atrial fibrillation pathophysiology and management. Circulation. 2015;7:495–502.

46. Huang WA, Shivkumar K, Vaseghi M. Device-based autonomic modulation in arrhythmia patients: the role of vagal nerve stimulation. Curr Treat Options Cardiovasc Med. 2015;17:379.
SUPPLEMENTAL MATERIAL
## Table S1. Percentage of Patients with Missing Variables.

| Variable                                      | Percent Missing |
|-----------------------------------------------|-----------------|
| Age                                           | 0               |
| Male                                          | 0               |
| BMI                                           | 26.6            |
| Race                                          | 1.3             |
| Portal Hypertension                           | 0               |
| Hepatitis C                                   | 0               |
| NASH (non alcoholic steatohepatitis)          | 0               |
| Alcohol Abuse                                 | 0               |
| Primary Liver Cancer                          | 0               |
| Hemodynamic Instability                       | 0               |
| Sleep Apnea                                   | 0               |
| Diabetes                                      | 0               |
| Hypertension                                  | 0               |
| Stroke                                        | 0               |
| Ischemic and/or Hemorrhagic Stroke            | 0               |
| Ischemic Stroke                               | 0               |
| Hemorrhagic Stroke                            | 0               |
| Coronary Artery Disease                       | 0               |
| Severe Valvular Disease                       | 0               |
| Diastolic Dysfunction                         | 0               |
| LV Ejection Fraction                          | 5.8             |
| Reduced LV Ejection Fraction (<50%)           | 5.8             |
| LA Moderate or Severe Enlargement             | 0               |
| LA Volume (mL)                                | 33.2            |
| LV hypertrophy                                | 0               |
| CHADS2VASc Score                              | 0               |
| HAS-BLED Score                                | 1.5             |
| MELD Score                                    | 1.5             |
| Abnormal TSH                                   | 68              |
| Abnormal Potassium/Magnesium                  | 16              |
| Beta Blocker Use                              | 0               |
| Class 1 Anti-arrhythmic Use                   | 0               |
| Amiodarone Use                                | 0               |
| Digoxin                                       | 0               |

BMI: body mass index, LV: left ventricle, LA: left atrium, MELD: Model for End Stage Liver Disease, TSH: thyroid stimulating hormone
Table S2. Univariable Analysis.

| Characteristic                                      | Hazard Ratios (95% C.I.) | P value |
|-----------------------------------------------------|--------------------------|---------|
| Age                                                 | 1.05 (1.03, 1.07)        | <0.001  |
| Male                                                | 1.29 (0.92, 1.8)         | 0.14    |
| BMI                                                 | 1.01 (0.99, 1.03)        | 0.52    |
| White                                               | 1.69 (1.23, 2.34)        | 0.001   |
| Portal Hypertension                                | 1.54 (1.1, 2.18)         | 0.013   |
| Hepatitis C                                         | 0.94 (0.68, 1.32)        | 0.73    |
| NASH (non-alcoholic steatohepatitis)                | 1.42 (1.01, 2)           | 0.042   |
| Alcohol Abuse                                       | 1.41 (0.99, 2.01)        | 0.059   |
| Primary Liver Cancer                                | 1.27 (0.89, 1.83)        | 0.19    |
| Hemodynamic Instability                             | 3.23 (2.09, 5)           | <0.001  |
| Sleep Apnea                                         | 3.33 (1.62, 6.84)        | 0.001   |
| Diabetes                                            | 1.65 (1.16, 2.35)        | 0.005   |
| Hypertension                                        | 1.72 (1.22, 2.42)        | 0.002   |
| Severe Valvular Disease                             | 7.34 (4.13, 13.05)       | <0.001  |
| Diastolic Dysfunction                               | 1.35 (0.85, 2.13)        | 0.21    |
| LV Ejection Fraction                                | 0.004 (0, 0.02)          | <0.001  |
| Reduced LV Ejection Fraction (<50%)                 | 2.40 (1.42, 4.04)        | 0.001   |
| LA Moderate or Severe Enlargement                   | 3.06 (1.89, 4.95)        | <0.001  |
| LA Volume (mL)                                      | 1.01 (1, 1.02)           | 0.002   |
| LV hypertrophy                                      | 2.54 (1.6, 4.02)         | <0.001  |
| MELD Score                                           | 1.09 (1.07, 1.11)        | <0.001  |
| 11-20                                               | 2.55 (1.38, 2.97)        | <0.001* |
| 21-30                                               | 5.68 (5.91, 4.72)        | *       |
| >30                                                 | 13.21 (10.85, 29.5)      | *       |
| Abnormal TSH                                         | 0.87 (0.48, 1.58)        | 0.65    |
| Abnormal Potassium/Magnesium                        | 1.02 (0.65, 1.6)         | 0.95    |

*P-value for the overall model containing MELD groups 11-20, 21-30, >30 with MELD group 1-10 used as the reference category. BMI: body mass index, LV: left ventricle, LA: left atrium, MELD: Model for End Stage Liver Disease, TSH: thyroid stimulating hormone
Table S3. Patient Characteristics With and Without Atrial Fibrillation.

| Characteristic                        | No AF     | AF        | P value |
|---------------------------------------|-----------|-----------|---------|
| Age, years                            | 51.8 ± 13.0 | 55.0 ± 8.9 | <0.001 |
| Male                                  | 938 (59.4) | 96 (64.4) | 0.228  |
| BMI                                   | 27.81 ± 7.1 | 29.2 ± 7.7 | 0.023  |
| White                                 | 589 (37.3) | 79 (53.0) | <0.001 |
| Portal Hypertension                   | 31.0       | 33.5       | 0.56   |
| Hepatitis C                           | 11.2       | 12.7       | 0.49   |
| Non-alcoholic steatohepatitis         | 20.7       | 19.5       | 0.79   |
| Alcohol Abuse                         | 0.0        | 0.0        | NA     |
| Primary Liver Cancer                  | 11.4       | 6.6        | 0.032  |
| Hemodynamic Instability               | 15.2       | 10.4       | 0.045  |
| Sleep Apnea                           | 1.0        | 2.3        | 0.014  |
| Diabetes                              | 12.1       | 12.2       | 0.92   |
| Hypertension                          | 16.0       | 15.4       | 0.90   |
| Severe Valvular Disease               | 1.4        | 3.3        | 0.006  |
| Diastolic Dysfunction                 | 45.5       | 57.4       | 0.12   |
| LV Ejection Fraction                  | 60.9 ± 7.8 | 59.3 ± 8.1 | 0.009  |
| Reduced LV Ejection Fraction (<50%)   | 6.1        | 5.1        | 0.64   |
| LA Moderate or Severe Enlargement     | 8.3        | 6.1        | 0.23   |
| LA Volume (mL)                        | 54.5 ± 26.5 | 61.1 ± 30.4 | 0.005  |
| LV hypertrophy                        | 8.2        | 6.9        | 0.49   |
| CHA2DS2-VASc Score                    | 1.16 ± 1.08 | 1.06 ± 1   | 0.16   |
| MELD Score                            | 15.0 ± 6.7 | 16.1 ± 7.1 | 0.027  |
| Abnormal TSH                          | 100.6      | 84.0       | 0.20   |
| Abnormal Potassium/Magnesium          | 68.5       | 54.2       | 0.045  |

Values are mean ± SD, n (%), or the number of new events per 100 person-years of follow-up. Continuous variables are time averaged values. BMI: body mass index, LV: left ventricle, LA: left atrium, MELD: Model for End Stage Liver Disease, TSH: thyroid stimulating hormone.
Table S4. Multivariable Cox proportional hazard ratios obtained using non-imputed data to evaluate factors associated with new onset AF.

| Variable                  | HR   | Lower 95% CI | Upper 95% CI | P-value |
|---------------------------|------|--------------|--------------|---------|
| Diabetes                  | 0.96 | 0.64         | 1.45         | 0.85    |
| Hypertension              | 1.01 | 0.67         | 1.51         | 0.97    |
| Age                       | 1.06 | 1.04         | 1.08         | <0.001  |
| Male                      | 1.1  | 0.76         | 1.58         | 0.62    |
| Portal Hypertension       | 0.96 | 0.66         | 1.41         | 0.84    |
| LA Enlargement            | 1.21 | 0.69         | 2.13         | 0.51    |
| LV Hypertrophy            | 1.2  | 0.7          | 2.05         | 0.51    |
| Hemodynamic Instability   | 1.8  | 1.09         | 2.98         | 0.02    |
| Sleep Apnea               | 2.48 | 1.16         | 5.33         | 0.02    |
| Reduced Ejection Fraction (<50%) | 2.71 | 1.5       | 4.91         | 0.001   |
| Valvular Heart Disease    | 2.67 | 1.26         | 5.66         | 0.01    |
| MELD Group 11-20          | 2.87 | 1.75         | 4.7          | <0.001  |
| MELD Group 21-30          | 6.51 | 3.62         | 11.72        | <0.001  |
| MELD Group >30            | 11.98 | 5.1      | 28.15        | <0.001  |

MELD: Model for End Stage Liver Disease; LA: left atrium; LV: left ventricle; HR: hazard ratio; CI: confidence interval
Table S5. Ischemic Stroke Risk by MELD category.

| Characteristic  | Hazard Ratios (95% C.I.) | P value |
|----------------|--------------------------|---------|
| MELD Score 11-20 | 1.25 (0.56, 2.8)         | <0.001* |
| MELD Score 21-30 | 2.89 (1.26, 6.61)        |         |
| MELD Score >30  | 15.79 (6.12, 40.72)      |         |

*P-value for the overall model containing MELD groups 11-20, 21-30, >30 with MELD group 1-10 used as the reference category.
Table S6. Hemorrhagic Stroke Risk by MELD category.

| Characteristic    | Hazard Ratios (95% C.I.) | P value |
|-------------------|--------------------------|---------|
| MELD Score 11-20  | 1.90 (0.41, 8.74)        | <0.001* |
| MELD Score 21-30  | 9.87 (2.32, 42)          |         |
| MELD Score >30    | 65.76 (14.28, 302.88)    |         |

*P-value for the overall model containing MELD groups 11-20, 21-30, >30 with MELD group 1-10 used as the reference category.